ClinicalTrials.gg
CompletedNCT00454207Updated Feb 21, 2021Results posted

Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension

A Phase 3 interventional study of sildenafil citrate (UK-92,480) in Pulmonary Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 8 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
7th of 18
44 · median 23
Started
2007
with 2 others
Phase 3
7 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
7 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 7th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1)

03

Conditions studied

  • Pulmonary Hypertension

Browse trials for

Keywords

  • Pulmonary Arterial Hypertension, PAH
04

In context

Pulmonary Arterial Hypertension Reclassified

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's enrollment of 44 is close to the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 16 and over, and classified as having pulmonary arterial hypertension
  • Subjects who meet the following conditions on right heart catheterization at screening or baseline: mean pulmonary arterial pressure of ≥ 25mmHg and pulmonary capillary wedge pressure of ≤ 15mmHg at rest
  • Subjects whose baseline 6-Minute Walk test distance is >100 m and \<450 m

Exclusion criteria

Exclusion Criteria:

  • Significant Hepatic and/or renal disorder
  • Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic ischemic optic neuropathy (NAION)
  • Subjects who are currently receiving nitrates or nitric oxide donors in any form, ritonavir, ketoconazole and itraconazole
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    sildenafil citrate (UK-92,480)

    sildenafil citrate 20 mg TID

    Drug: sildenafil citrate (UK-92,480)

Interventions

07

What researchers measure

Primary outcomes

  1. Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:total distance walked during the 6-minute walk test.

    Time frame: Baseline, Week 12

  2. Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Mean pulmonary arterial pressure at Week 12 minus mean pulmonary arterial pressure at baseline.

    Time frame: Baseline, Week 12

  3. Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Pulmonary vascular resistance at Week 12 minus pulmonary vascular resistance at baseline

    Time frame: Baseline, Week 12

  4. Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Cardiac output at Week 12 minus cardiac output at baseline

    Time frame: Baseline, week 12

Secondary outcomes

  1. Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I

    Change:6-minute walk distance at Week 8 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.

    Time frame: Baseline, Week 8

  2. Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Systolic pulmonary arterial pressure at Week 12 minus Systolic pulmonary arterial pressure at baseline.

    Time frame: Baseline, Week 12

  3. Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Diastolic pulmonary arterial pressure at Week 12 minus diastolic pulmonary arterial pressure at baseline.

    Time frame: Baseline, Week 12

  4. Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Systolic systemic blood pressure at Week 12 minus systolic systemic blood pressure at baseline.

    Time frame: Baseline, Week 12

  5. Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Diastolic systemic blood pressure at Week 12 minus diastolic systemic blood pressure at baseline.

    Time frame: Baseline, Week 12

  6. Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Mean systemic blood pressure:diastolic blood pressure+(systolic blood pressure-diastolic blood pressure)/3. Change:Mean systemic blood pressure at Week 12 minus mean systemic blood pressure at baseline.

    Time frame: Baseline, Week 12

  7. Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Pulmonary capillary wedge pressure at Week 12 minus pulmonary capillary wedge pressure at baseline.

    Time frame: Baseline, Week 12

  8. Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Right atrial pressure at Week 12 minus right atrial pressure at baseline.

    Time frame: Baseline, Week 12

  9. Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Cardiac index at Week 12 minus cardiac index at baseline.

    Time frame: Baseline, Week 12

  10. Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Heart rate at Week 12 minus heart rate at baseline.

    Time frame: Baseline, Week 12

  11. Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Pulmonary vascular resistance index at Week 12 minus pulmonary vascular resistance index at baseline.

    Time frame: Baseline, Week 12

  12. Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Systemic vascular resistance at Week 12 minus systemic vascular resistance at baseline.

    Time frame: Baseline, Week 12

  13. Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Systemic vascular resistance index at Week 12 minus systemic vascular resistance index at baseline.

    Time frame: baseline, Week 12

  14. Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Mixed venous oxygen saturation at Week 12 minus mixed venous oxygen saturation at baseline.

    Time frame: Baseline, Week 12

  15. Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Arterial oxygen saturation at Week 12 minus arterial oxygen saturation at baseline.

    Time frame: Baseline, Week 12

  16. Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Arterial oxygen partial pressure at Week 12 minus arterial oxygen partial pressure at baseline.

    Time frame: baseline, Week 12

  17. Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I

    Change:Partial pressure of mixed venous oxygen at Week 12 minus partial pressure of mixed venous oxygen at baseline.

    Time frame: Baseline, Week 12

  18. Changes in the World Health Organization (WHO) Functional Class of Pulmonary Arterial Hypertension From Baseline at Weeks 12 in Participants Who Entered the Study From Part I

    The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).

    Time frame: Baseline, Week 12

  19. Changes in the BORG Dyspnoea Score From Baseline at Week 8 and Week 12 in Participants Who Entered the Study From Part I

    Change:BORG dyspnoea score at Week 8 and Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.

    Time frame: Baseline, Week 8, Week 12

  20. Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 4, Week 8 and Week 12 in Participants Who Entered the Study From Part I

    Change:Plasma brain natriuretic peptide level at Week 4, Week 8 and Week 12 minus plasma brain natriuretic peptide level at baseline

    Time frame: Baseline, Week 4, Week 8, Week 12

  21. Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II

    Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.

    Time frame: Baseline, Week 12

  22. Change in the World Health Organization (WHO) Functional Class From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II

    The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).

    Time frame: Baseline, Week 12

  23. Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II

    Change:BORG dyspnoea score at Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.

    Time frame: Baseline, Week 12

  24. Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II

    Change:Plasma brain natriuretic peptide level at Week 12 minus plasma brain natriuretic peptide level at baseline

    Time frame: Baseline, Week 12

  25. Maximum Plasma Concentrations (Cmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320

    Maximum plasma concentrations was calculated from the observed value of plasma concentrations in each participant

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing

  26. Time to First Occurrence of Maximum Plasma Concentrations (Tmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320

    Time to first occurrence of maximum plasma concentrations were calculated from the observed value of plasma concentrations in each participant.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing

  27. The Area Under the Curve (AUC) From Time 0 to Time 8 Hour of Sildenafil and Sildenafil's Metabolite, UK-103,320

    The area under the curve from time 0 to time 8 hour was calculated from area under the curve in each perticipant on the date of blood sampling using the linear/log trapezoidal rule

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing

  28. The Average Plasma Concentration (Css,av) of Sildenafil at Steady State

    The average plasma concentration of sildenafil at steady state was calculated from the area under the curve from time 0 to 8 hour/dosing interval (8 hours).

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing

  29. The Average Plasma Trough Concentration (Ctrough) of Sildenafil

    The average plasma trough concentration of sildenafil was calculated from the observed value before administration of the drug in each participants.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing

  30. Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    The total number of participants with laboratory test abnormalities without regard to baseline abnormality.

    Time frame: Baseline up to 1.3 years

08

Results

Posted Sep 9, 2010

Participant flow

Eight centers in Japan

Participant flow — Overall Study
MilestoneSildenafil: Participant Who Entered the Study From Part ISildenafil: Participants Who Entered the Study From Part II
Started2123
Completed1721
Not completed42
Withdrew: Adverse event31
Withdrew: Lack of efficacy10
Withdrew: Protocol violation01

Outcome measures

PrimaryChange in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:total distance walked during the 6-minute walk test.

Time frame:
Baseline, Week 12
Reported as:
Mean · meters
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I
metersSildenafil: Part I
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I84.2 ± 74.9
PrimaryChange in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Mean pulmonary arterial pressure at Week 12 minus mean pulmonary arterial pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I-4.7 ± 8.2
PrimaryChange in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Pulmonary vascular resistance at Week 12 minus pulmonary vascular resistance at baseline

Time frame:
Baseline, Week 12
Reported as:
Mean · dyne·second/centimeter^5
Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I
dyne·second/centimeter^5Sildenafil:Part I
Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I-246.49 ± 301.17
SecondaryChange in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I

Change:6-minute walk distance at Week 8 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.

Time frame:
Baseline, Week 8
Reported as:
Mean · meters
Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I
metersSildenafil:Part I
Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I87.5 ± 75.3
SecondaryChange in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Systolic pulmonary arterial pressure at Week 12 minus Systolic pulmonary arterial pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I-3.4 ± 13.4
SecondaryChange in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Diastolic pulmonary arterial pressure at Week 12 minus diastolic pulmonary arterial pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I-3.2 ± 8.3
SecondaryChange in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Systolic systemic blood pressure at Week 12 minus systolic systemic blood pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I0.7 ± 16.5
SecondaryChange in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Diastolic systemic blood pressure at Week 12 minus diastolic systemic blood pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I-3.1 ± 9.0
SecondaryChange in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Mean systemic blood pressure:diastolic blood pressure+(systolic blood pressure-diastolic blood pressure)/3. Change:Mean systemic blood pressure at Week 12 minus mean systemic blood pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I-0.9 ± 12.9
PrimaryChange in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Cardiac output at Week 12 minus cardiac output at baseline

Time frame:
Baseline, week 12
Reported as:
Mean · liter/minute
Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I
liter/minuteSildenafil:Part I
Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I0.556 ± 1.000
SecondaryChange in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Pulmonary capillary wedge pressure at Week 12 minus pulmonary capillary wedge pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I0.68 ± 3.14
SecondaryChange in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Right atrial pressure at Week 12 minus right atrial pressure at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I-0.3 ± 4.4
SecondaryChange in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Cardiac index at Week 12 minus cardiac index at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · liter/minute/meter^2
Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
liter/minute/meter^2Sildenafil:Part I
Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I0.32 ± 0.62
SecondaryChange in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Heart rate at Week 12 minus heart rate at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · beats/minute
Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I
beats/minuteSildenafil:Part I
Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I-4.14 ± 7.45
SecondaryChange in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Pulmonary vascular resistance index at Week 12 minus pulmonary vascular resistance index at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · dyne*second/centimeter^5/meter^2
Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
dyne*second/centimeter^5/meter^2Sildenafil:Part I
Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I-382.00 ± 491.80
SecondaryChange in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Systemic vascular resistance at Week 12 minus systemic vascular resistance at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · dyne*second/centimeter^5
Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I
dyne*second/centimeter^5Sildenafil:Part I
Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I-265.77 ± 785.52
SecondaryChange in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Systemic vascular resistance index at Week 12 minus systemic vascular resistance index at baseline.

Time frame:
baseline, Week 12
Reported as:
Mean · dyne*second/centimeter^5/meter^2
Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
dyne*second/centimeter^5/meter^2Sildenafil:Part I
Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I-409.89 ± 1271.30
SecondaryChange in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Mixed venous oxygen saturation at Week 12 minus mixed venous oxygen saturation at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent saturation
Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I
percent saturationSildenafil:Part I
Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I2.91 ± 9.05
SecondaryChange in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Arterial oxygen saturation at Week 12 minus arterial oxygen saturation at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent saturation
Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I
percent saturationSildenafil:Part I
Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I0.440 ± 5.437
SecondaryChange in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Arterial oxygen partial pressure at Week 12 minus arterial oxygen partial pressure at baseline.

Time frame:
baseline, Week 12
Reported as:
Mean · mmHg
Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I-2.02 ± 11.17
SecondaryChange in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I

Change:Partial pressure of mixed venous oxygen at Week 12 minus partial pressure of mixed venous oxygen at baseline.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I
mmHgSildenafil:Part I
Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I0.57 ± 4.35
SecondaryChanges in the World Health Organization (WHO) Functional Class of Pulmonary Arterial Hypertension From Baseline at Weeks 12 in Participants Who Entered the Study From Part I

The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).

Time frame:
Baseline, Week 12
Reported as:
Number · participants
Changes in the World Health Organization (WHO) Functional Class of Pulmonary Arterial Hypertension From Baseline at Weeks 12 in Participants Who Entered the Study From Part I
participantsSildenafil:Part I , Functional Class at Baseline: ISildenafil:Part I, Functional Class at Baseline: IISildenafil, Part I, Functional Class at Baseline: IIISildenafil, Part I, Functional Class at Baseline:IV
Functional class at Week 12:I—01—
Functional class at Week 12:II—65—
Functional class at Week 12:III—17—
Functional class at Week 12:IV—00—
SecondaryChanges in the BORG Dyspnoea Score From Baseline at Week 8 and Week 12 in Participants Who Entered the Study From Part I

Change:BORG dyspnoea score at Week 8 and Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.

Time frame:
Baseline, Week 8, Week 12
Reported as:
Mean · scores on a scale
Changes in the BORG Dyspnoea Score From Baseline at Week 8 and Week 12 in Participants Who Entered the Study From Part I
scores on a scaleSildenafil:Part I
Week 8 (n=19, 0)-0.84 ± 1.89
Week 12 (n=20, 6)-0.95 ± 1.94
SecondaryChanges in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 4, Week 8 and Week 12 in Participants Who Entered the Study From Part I

Change:Plasma brain natriuretic peptide level at Week 4, Week 8 and Week 12 minus plasma brain natriuretic peptide level at baseline

Time frame:
Baseline, Week 4, Week 8, Week 12
Reported as:
Mean · picograms/milliliter
Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 4, Week 8 and Week 12 in Participants Who Entered the Study From Part I
picograms/milliliterSildenafil:Part I
Week 4 (n=20, 0)-78.00 ± 166.41
Week 8 (n=19, 0)-88.25 ± 178.39
Week 12 (n=20, 7)-61.82 ± 209.96
SecondaryChange in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II

Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.

Time frame:
Baseline, Week 12
Reported as:
Mean · meters
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
metersSildenafil:Part II
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II-23.5 ± 34.1
SecondaryChange in the World Health Organization (WHO) Functional Class From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II

The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).

Time frame:
Baseline, Week 12
Reported as:
Number · participants
Change in the World Health Organization (WHO) Functional Class From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
participantsSildenafil:Part II, Functional Class at Baseline: ISildenafil:Part II, Functional Class at Baseline: IISildenafil: Part II, Functional Class at Baseline: IIISildenafil: Part II, Functional Class at Baseline: IV
Functional class at Week 12: I10——
Functional class at Week 12: II05——
Functional class at Week 12: III01——
Functional class at Week 12: IV00——
SecondaryChanges in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II

Change:BORG dyspnoea score at Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.

Time frame:
Baseline, Week 12
Reported as:
Mean · scores on a scale
Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
scores on a scaleSildenafil: Part II
Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II0.33 ± 1.21
SecondaryChanges in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II

Change:Plasma brain natriuretic peptide level at Week 12 minus plasma brain natriuretic peptide level at baseline

Time frame:
Baseline, Week 12
Reported as:
Mean · picograms/milliliter
Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II
picograms/milliliterSildenafil:Part II
Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II15.91 ± 55.94
SecondaryMaximum Plasma Concentrations (Cmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320

Maximum plasma concentrations was calculated from the observed value of plasma concentrations in each participant

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
Reported as:
Mean · nanograms/milliliter
Maximum Plasma Concentrations (Cmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320
nanograms/milliliterSildenafil:Pharmacokinetic Analysis Participant
Sildenafil164.88 ± 74.78
Sildenafil's Metabolite, UK-103,32087.27 ± 30.67
SecondaryTime to First Occurrence of Maximum Plasma Concentrations (Tmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320

Time to first occurrence of maximum plasma concentrations were calculated from the observed value of plasma concentrations in each participant.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
Reported as:
Mean · hours
Time to First Occurrence of Maximum Plasma Concentrations (Tmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320
hoursSildenafil:Pharmacokinetic Analysis Participant
Sildenafil1.102 ± 0.499
Sildenafil's Metabolite, UK-103,3201.611 ± 1.024
SecondaryThe Area Under the Curve (AUC) From Time 0 to Time 8 Hour of Sildenafil and Sildenafil's Metabolite, UK-103,320

The area under the curve from time 0 to time 8 hour was calculated from area under the curve in each perticipant on the date of blood sampling using the linear/log trapezoidal rule

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
Reported as:
Mean · nanogram*hour/milliliter
The Area Under the Curve (AUC) From Time 0 to Time 8 Hour of Sildenafil and Sildenafil's Metabolite, UK-103,320
nanogram*hour/milliliterSildenafil:Pharmacokinetic Analysis Participant
Sildenafil545.14 ± 294.88
Sildenafil's Metabolite, UK-103,320365.85 ± 186.55
SecondaryThe Average Plasma Concentration (Css,av) of Sildenafil at Steady State

The average plasma concentration of sildenafil at steady state was calculated from the area under the curve from time 0 to 8 hour/dosing interval (8 hours).

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
Reported as:
Mean · nanograms/milliliter
The Average Plasma Concentration (Css,av) of Sildenafil at Steady State
nanograms/milliliterSildenafil:Pharmacokinetic Analysis Participant
The Average Plasma Concentration (Css,av) of Sildenafil at Steady State68.14 ± 36.86
SecondaryThe Average Plasma Trough Concentration (Ctrough) of Sildenafil

The average plasma trough concentration of sildenafil was calculated from the observed value before administration of the drug in each participants.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
Reported as:
Mean · nanograms/milliliter
The Average Plasma Trough Concentration (Ctrough) of Sildenafil
nanograms/milliliterSildenafil:Pharmacokinetic Analysis Participant
The Average Plasma Trough Concentration (Ctrough) of Sildenafil19.608 ± 12.438
SecondaryLaboratory Test Abnormalities (Without Regard to Baseline Abnormality)

The total number of participants with laboratory test abnormalities without regard to baseline abnormality.

Time frame:
Baseline up to 1.3 years
Reported as:
Number · participants
Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
participantsSildenafil: Part I and Part II
Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)35

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sildenafil: Part I and Part II—7/44 (15.9%)42/44 (95.5%)
Most frequent serious events
Most frequent serious events
EventSildenafil: Part I and Part II
Cardiac failureCardiac disorders2/44
AnorexiaMetabolism and nutrition disorders2/44
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders2/44
CataractEye disorders1/44
NauseaGastrointestinal disorders1/44
NasopharyngitisInfections and infestations1/44
PneumoniaInfections and infestations1/44
Platelet count decreasedInvestigations1/44
Scleroderma renal crisisRenal and urinary disorders1/44
Most frequent other events
Showing 10 of 13
Most frequent other events
EventSildenafil: Part I and Part II
NasopharyngitisInfections and infestations17/44
HeadacheNervous system disorders11/44
FlushingVascular disorders10/44
PyrexiaGeneral disorders5/44
DiarrhoeaGastrointestinal disorders4/44
FallInjury, poisoning and procedural complications4/44
DizzinessNervous system disorders4/44
Oedema peripheralGeneral disorders3/44
Platelet count decreasedInvestigations3/44
Back painMusculoskeletal and connective tissue disorders3/44

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sildenafil: Participant Who Entered the Study From Part ISildenafil: Participants Who Entered the Study From Part IITotal
<=18 years011
Between 18 and 65 years192039
>=65 years224
Sex: Female, Male
Sex: Female, Male(Participants)Sildenafil: Participant Who Entered the Study From Part ISildenafil: Participants Who Entered the Study From Part IITotal
Female172138
Male426
Region of Enrollment
Region of Enrollment(participants)Sildenafil: Participant Who Entered the Study From Part ISildenafil: Participants Who Entered the Study From Part IITotal
Japan212344
09

Study locations

8 sites
  • Pfizer Investigational Site
    Chiba-shi, Chiba, Japan
  • Pfizer Investigational Site
    Kanazawa, Ishikawa, Japan
  • Pfizer Investigational Site
    Tsu-shi, Mie, Japan
  • Pfizer Investigational Site
    Okayama City, Okayama, Japan
  • Pfizer Investigational Site
    Hamamatsu-shi, Shizuoka, Japan
  • Pfizer Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Tokyo, Japan
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2007
First posted
Mar 30, 2007
Start
Apr 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Sep 9, 2010
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00454207
Responsible party
Sponsor
First posted
Mar 30, 2007
Start date
Apr 2007
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Sep 9, 2010
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion